Brooke William W 4

What Happened

• William W. Brooke, a director of MaxCyte, received equity awards on June 17, 2026. The filing shows two grants: 30,421 restricted stock units (RSUs) and 49,579 RSUs recorded as a derivative award. Both grants were reported at $0.00 per share (no cash paid), for a total of 80,000 RSUs. These RSUs are contingent rights to receive shares of the company's common stock and are grants rather than open‑market purchases or sales.

Key Details

• Transaction date: 2026-06-17; filing date: 2026-06-22 (appears later than the typical two-business-day Form 4 filing window).
• Prices reported: $0.00 per share for both grants.
• Total RSUs granted: 30,421 (direct) + 49,579 (derivative) = 80,000 RSUs.
• Shares owned after transaction: Not disclosed in the provided excerpt.
• Footnotes:
  • F1: Each RSU represents a contingent right to receive one share of MaxCyte common stock.
  • F2: The 49,579-share annual grant was made under the company’s Equity Grant Policy for non-employee directors and vests on June 17, 2027, subject to continuous service.
• Filing timeliness: The report was filed five days after the transaction date (filed 6/22 for a 6/17 transaction), which appears to be late relative to the usual two-business-day Form 4 deadline.

Context

• RSU grants to non-employee directors are a common form of compensation and do not represent an immediate cash purchase or sale of shares; they convert to shares only upon vesting (here, likely one year later if the director remains in service).
• Because this is an award/grant (code A) rather than a purchase or sale, it should be interpreted as compensation, not a direct signal of the insider buying or selling stock.